Statement on Dengvaxia® issued by Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) with support from International Vaccine Access Center

There is a strong public health need for a dengue vaccine. Recently, concerns have arisen in the Philippines about the safety of Dengvaxia®, a dengue vaccine developed by Sanofi Pasteur (SP). The concerns arose after SP released new long-term clinical trial results that came out based on the recent availability of the NS1 testing and imputation, which found that the vaccine could cause even more severe cases of dengue for those who were not seropositive (those who had not been infected with dengue prior to vaccination). In light of these events, the World Health Organization (WHO) has clarified their position on use of the dengue vaccine.

Dr. Dagna Constenla, Director of Economics & Finance at the International Vaccine Access Center at Johns Hopkins Bloomberg School of Public Health, is a member of the Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC). GDAC works to prevent dengue and other Aedes-transmitted diseases, by sharing information and advice to inform disease prevention strategies.

The consortium developed of the recently issued statement on Long-Term Safety of Sanofi Pasteur’s Dengvaxia®:

Global Dengue & Aedes-Transmitted Diseases Consortium (GDAC) Statement on Long-Term Safety of Sanofi Pasteur’s Dengvaxia®

Dr. Constenla had additional comments about the company’s new recommendations:

“Dengue vaccine introduction decisions are complex. Sanofi Pasteur’s new recommendations makes vaccine introduction decisions more complicated, even precarious. The relevant cost-benefit factors will need to be reassessed in light of these events—especially because the recommendation to collect blood samples prior to vaccine administration to indicate whether individuals have been previously infected may not be practical.”

Related content on Dengvaxia®:


  • WHO Position on Dengue Vaccine – WHO, 2016 
  • WHO update on Dengue Vaccine – WHO, Dec 5, 2017
  • Updated Questions and Answers related to information presented in the Sanofi Pasteur press release on 30 November 2017 with regards to the dengue vaccine Dengvaxia®  – WHO, 2017 
  • Sanofi Updates Information on Dengue Vaccine – Sanofi
  • FDA Advisory No. 2017-318 || Suspension of Sale/Marketing/Distribution of Sanofi Pasteur, Inc.’s Tetravalent Vaccine (Live, Attenuated) (Dengvaxia) – FDA, 2017


  • Philippines Suspends Dengue Shots After Drug Firm’s Warning – NY Times
  • Sanofi scandal in Philippines could spread dangerour mistrust of vaccines – Stat News
  • The Problem with Vaccines… – PhilStar Global
  • Philippines plan to sue Sanofi over dengue vaccine – France 24
  • Exclusive – Philippines defied experts’ advice in pursuing dengue immunization programme – Reuters
  • Philippines Orders Probe into Vaccine, Sanofi Says No Deaths Reported – NY Times

Journal Articles

  • Cost-effectiveness of dengue vaccination in ten endemic countries – Vaccine, 2018
  • Which Dengue Vaccine Approach is the Most Promising, and Should We Be concerned About Enhanced Disease after Vaccination? – Cold Spring Harbor Perspectives in Biology, 2017
  • Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? – Expert Review of Vaccines, 2016